• +1-646-491-9876
    • +91-20-67278686

    Search

    High-Grade Glioma Pipeline Review H1 2017

    High-Grade Glioma Pipeline Review H1 2017

    • Report Code ID: RW0001858672
    • Category Pharmaceuticals
    • No. of Pages 253
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    High-Grade Glioma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H1 2017, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

    Highly grade gliomas (HGG) are tumors of the central nervous system (CNS) that arising from transformed cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, Dysregulated ap-petite, paralyses and seizures. Treatment includes Chemotherapy and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 12, 11, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

    High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    High-Grade Glioma - Overview
    High-Grade Glioma - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    High-Grade Glioma - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    High-Grade Glioma - Companies Involved in Therapeutics Development
    Advenchen Laboratories LLC
    AngioChem Inc
    Arog Pharmaceuticals Inc
    Astellas Pharma Inc
    Athenex Inc
    Bayer AG
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    BTG Plc
    Cavion LLC
    CBT Pharmaceuticals Inc
    Concordia International Corp
    DelMar Pharmaceuticals Inc
    Ipsen SA
    Millennium Pharmaceuticals Inc
    Nektar Therapeutics
    Novartis AG
    Ono Pharmaceutical Co Ltd
    Sanofi
    Sorrento Therapeutics Inc
    Sumitomo Dainippon Pharma Co Ltd
    Targepeutics Inc
    Tocagen Inc
    ZIOPHARM Oncology Inc
    High-Grade Glioma - Drug Profiles
    AdRTSIL-12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    afatinib dimaleate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    alisertib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    apatinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bendamustine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMX-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cabazitaxel - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CBT-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Gliomas - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for High-Grade Glioma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    crenolanib besylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CYT-107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dabrafenib mesylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dianhydrogalactitol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DSP-7888 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    etirinotecan pegol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    flucytosine + TBio-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    flucytosine ER + vocimagene amiretrorepvec - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GB-13 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HSV-1716 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ipilimumab + nivolumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    irinotecan hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    irinotecan hydrochloride + TBio-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    irinotecan hydrochloride CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KX-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mibefradil dihydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nivolumab - Drug Profile
    R&D Progress
    Oncolytic Virus for High-Grade Glioma and Melanoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    paclitaxel trevatide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    porfimer sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RRX-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sorafenib tosylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    High-Grade Glioma - Dormant Projects
    High-Grade Glioma - Discontinued Products
    High-Grade Glioma - Product Development Milestones
    Featured News & Press Releases
    May 11, 2017: Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting
    Mar 16, 2017: Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia
    Feb 23, 2017: Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma
    Nov 21, 2016: Tocagen Presents Updated Clinical and Preclinical Data at Scientific Meetings
    Nov 10, 2016: Tocagen to Present Clinical and Preclinical Data at Upcoming Scientific Meetings
    Oct 05, 2016: Tocagen Presents Updated Tumor Response Data for its Cancer-Selective Gene Therapy
    Sep 30, 2016: Tocagen to Present Clinical and Preclinical Data at Two Scientific Meetings
    May 13, 2016: Tocagen to Present Clinical and Preclinical Data at Three Scientific Meetings
    May 03, 2016: Tocagen Presents Intravenous Toca 511 Clinical Data at the 84th AANS Annual Scientific Meeting
    Apr 13, 2016: Tocagen to Present Data from Clinical Trials and Preclinical Programs at Four Scientific Conferences
    Nov 23, 2015: Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology
    Nov 18, 2015: Tocagen to Present Interim Results from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology
    Jul 09, 2015: FDA Grants Fast Track Designation to Tocagen's Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma
    Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
    May 28, 2015: Cavion to Present Clinical Trial Data at ASCO
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for High-Grade Glioma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H1 2017
    High-Grade Glioma - Pipeline by AngioChem Inc, H1 2017
    High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H1 2017
    High-Grade Glioma - Pipeline by Astellas Pharma Inc, H1 2017
    High-Grade Glioma - Pipeline by Athenex Inc, H1 2017
    High-Grade Glioma - Pipeline by Bayer AG, H1 2017
    High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    High-Grade Glioma - Pipeline by Bristol-Myers Squibb Company, H1 2017
    High-Grade Glioma - Pipeline by BTG Plc, H1 2017
    High-Grade Glioma - Pipeline by Cavion LLC, H1 2017
    High-Grade Glioma - Pipeline by CBT Pharmaceuticals Inc, H1 2017
    High-Grade Glioma - Pipeline by Concordia International Corp, H1 2017
    High-Grade Glioma - Pipeline by DelMar Pharmaceuticals Inc, H1 2017
    High-Grade Glioma - Pipeline by Ipsen SA, H1 2017
    High-Grade Glioma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    High-Grade Glioma - Pipeline by Nektar Therapeutics, H1 2017
    High-Grade Glioma - Pipeline by Novartis AG, H1 2017
    High-Grade Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    High-Grade Glioma - Pipeline by Sanofi, H1 2017
    High-Grade Glioma - Pipeline by Sorrento Therapeutics Inc, H1 2017
    High-Grade Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
    High-Grade Glioma - Pipeline by Targepeutics Inc, H1 2017
    High-Grade Glioma - Pipeline by Tocagen Inc, H1 2017
    High-Grade Glioma - Pipeline by ZIOPHARM Oncology Inc, H1 2017
    High-Grade Glioma - Dormant Projects, H1 2017
    High-Grade Glioma - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for High-Grade Glioma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Advenchen Laboratories LLC
    AngioChem Inc
    Arog Pharmaceuticals Inc
    Astellas Pharma Inc
    Athenex Inc
    Bayer AG
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    BTG Plc
    Cavion LLC
    CBT Pharmaceuticals Inc
    Concordia International Corp
    DelMar Pharmaceuticals Inc
    Ipsen SA
    Millennium Pharmaceuticals Inc
    Nektar Therapeutics
    Novartis AG
    Ono Pharmaceutical Co Ltd
    Sanofi
    Sorrento Therapeutics Inc
    Sumitomo Dainippon Pharma Co Ltd
    Targepeutics Inc
    Tocagen Inc
    ZIOPHARM Oncology Inc

    Request for Sample

    Report Url https://www.reportsweb.com//high-grade-glioma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//high-grade-glioma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//high-grade-glioma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments